Savant HWP Inc.

Aiming to interrupt addictions, at a basic level

The founders of Savant HWP Inc. believe they have identified a molecule that could prove effective in treating many kinds of substance as well as behavioral addictions, because it appears to influence relevant brain chemistry at a fundamental level. Its compound binds to the alpha-3-beta-4 nicotinic acetylcholine receptor and appears to indirectly regulate production of dopamine in the mid-brain.

Savant HWP Inc.

655 Skyway Road

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By 

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By 

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.

AstraZeneca Launches At-Home Flu Vaccine Amid Industry DTC Push

 

The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.